 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in UAMS Profiles by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 1 | 2 | | 2024 | 3 | 4 | 7 | | 2023 | 1 | 2 | 3 | | 2022 | 1 | 3 | 4 | | 2021 | 9 | 1 | 10 | | 2020 | 7 | 1 | 8 | | 2019 | 0 | 6 | 6 | | 2018 | 2 | 1 | 3 | | 2017 | 1 | 1 | 2 | | 2016 | 3 | 1 | 4 | | 2015 | 6 | 2 | 8 | | 2014 | 4 | 3 | 7 | | 2013 | 8 | 6 | 14 | | 2012 | 4 | 3 | 7 | | 2011 | 3 | 3 | 6 | | 2010 | 4 | 1 | 5 | | 2009 | 1 | 3 | 4 | | 2008 | 6 | 5 | 11 | | 2007 | 2 | 2 | 4 | | 2006 | 1 | 2 | 3 | | 2005 | 2 | 3 | 5 | | 2004 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles over the past ten years.
-
Tran P, Moccia M, Wang X, Brescia A, Federico G, Gunaganti N, Wang Z, Yang M, Wang M, Jabali B, Yan W, Frett B, Santoro M, Carlomagno F, Li HY. Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor. Eur J Med Chem. 2025 Sep 15; 294:117735.
-
Neill NE, Mauro LA, Pennisi A. Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer. Curr Treat Options Oncol. 2025 Apr; 26(4):302-312.
-
Wang X, Sato AY, Marino S, Akel N, Boysen G, Basnakian AG, Bellido TM, Li HY. Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss. J Med Chem. 2024 Nov 28; 67(22):20708-20720.
-
Han S, Tushoski-Alem?n GW, Zhang P, Zheng G, Zhou D, Huo Z, Licht J, George TJ, Allegra C, Trevino JG, Hughes SJ. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Neoplasia. 2025 Jan; 59:101070.
-
Chen CB, Wang CW, Lu CW, Chen WT, Zhou BR, Chu CY, Hsu SF, Yang CT, Wen-Cheng Chang J, Yang CK, Wang CL, Fang YF, Hsu PC, Hua CC, Wu CE, Ko HW, Chen KC, Yang YC, Tseng HC, Cheng AY, Tseng LC, Shih FY, Hung SI, Huang CY, Chung WH. Class I HLA Alleles Are Associated With an Increased Risk of Osimertinib-Induced Hypersensitivity. J Allergy Clin Immunol Pract. 2025 Jan; 13(1):143-154.e10.
-
Xia J, Zhao H, Edmondson JL, Koss B, Zhan F. Role of NEK2 in tumorigenesis and tumor progression. Trends Mol Med. 2025 Jan; 31(1):79-93.
-
Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, Lin HM, Dimou A. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Adv Ther. 2024 Aug; 41(8):3217-3231.
-
Hanley MJ, Zhang S, Griffin R, Zhu SX, Fram RJ, Lin J, Venkatakrishnan K, Gupta N. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Invest New Drugs. 2024 Aug; 42(4):343-352.
-
Ezzati S, Salib S, Balasubramaniam M, Aboud O. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities. Int J Mol Sci. 2024 Feb 15; 25(4).
-
Wang X, DeFilippis RA, Weldemichael T, Gunaganti N, Tran P, Leung YK, Shah NP, Li HY. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. Eur J Med Chem. 2024 Jan 15; 264:115977.
-
Wang X, DeFilippis RA, Leung YK, Shah NP, Li HY. N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants. Bioorg Chem. 2024 02; 143:106966.
-
Gupta N, Hanley MJ, Griffin RJ, Zhang P, Venkatakrishnan K, Sinha V. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clin Pharmacokinet. 2023 08; 62(8):1063-1079.
-
Cawich I, Armstrong EJ, George JC, Golzar J, Shishehbor MH, Razavi M, Lee V, Ouriel K. Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee. J Endovasc Ther. 2024 08; 31(4):562-575.
-
Acharya B, Frett B. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present). Expert Opin Ther Pat. 2022 Oct; 32(10):1067-1077.
-
Taniguchi H, Caeser R, Chavan SS, Zhan YA, Chow A, Manoj P, Uddin F, Kitai H, Qu R, Hayatt O, Shah NS, Quintanal Villalonga ?, Allaj V, Nguyen EM, Chan J, Michel AO, Mukae H, de Stanchina E, Rudin CM, Sen T. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022 05 17; 39(7):110814.
-
Zhang L, Moccia M, Briggs DC, Bharate JB, Lakkaniga NR, Knowles P, Yan W, Tran P, Kharbanda A, Wang X, Leung YK, Frett B, Santoro M, McDonald NQ, Carlomagno F, Li HY. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. J Med Chem. 2022 01 27; 65(2):1536-1551.
-
Kemps PG, Picarsic J, Durham BH, H?lias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JAM, Verdijk RM, Flucke UE, Hogendoorn PCW, Woei-A-Jin FJSH, Sciot R, Beilken A, Feuerhake F, Ebinger M, M?hle R, Fend F, Bornemann A, Wiegering V, Ernestus K, M?ry T, Gryniewicz-Kwiatkowska O, Dembowska-Baginska B, Evseev DA, Potapenko V, Baykov VV, Gaspari S, Rossi S, Gessi M, Tamburrini G, H?ritier S, Donadieu J, Bonneau-Lagacherie J, Lamaison C, Farnault L, Fraitag S, Julli? ML, Haroche J, Collin M, Allotey J, Madni M, Turner K, Picton S, Barbaro PM, Poulin A, Tam IS, El Demellawy D, Empringham B, Whitlock JA, Raghunathan A, Swanson AA, Suchi M, Brandt JM, Yaseen NR, Weinstein JL, Eldem I, Sisk BA, Sridhar V, Atkinson M, Massoth LR, Hornick JL, Alexandrescu S, Yeo KK, Petrova-Drus K, Peeke SZ, Mu?oz-Arcos LS, Leino DG, Grier DD, Lorsbach R, Roy S, Kumar AR, Garg S, Tiwari N, Schafernak KT, Henry MM, van Halteren AGS, Abla O, Diamond EL, Emile JF. ALK-positive?histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022 01 13; 139(2):256-280.
-
Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, Bekaii-Saab TS, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology. 2022 01; 75(1):43-58.
-
Pang Y, Yu G, Butler M, Sindiri S, Song YK, Wei JS, Wen X, Chou HC, Quezado M, Pack S, Xi L, Abdullaev Z, Kim O, Ranjan A, Merchant M, Antony R, Boris L, Aboud O, Kamson D, Kaplan R, Mackey M, Camphausen K, Zaghloul K, Armstrong TS, Gilbert MR, Aldape K, Holdhoff M, Khan J, Wu J. Report of Canonical BCR-ABL1 Fusion in Glioblastoma. JCO Precis Oncol. 2021; 5.
-
Saha D, Ryan KR, Lakkaniga NR, Acharya B, Garcia NG, Smith EL, Frett B. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. J Med Chem. 2021 08 26; 64(16):11747-11773.
-
Zhang L, Lakkaniga NR, Bharate JB, Mcconnell N, Wang X, Kharbanda A, Leung YK, Frett B, Shah NP, Li HY. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. Eur J Med Chem. 2021 Dec 05; 225:113776.
-
Moccia M, Yang D, Lakkaniga NR, Frett B, McConnell N, Zhang L, Brescia A, Federico G, Zhang L, Salerno P, Santoro M, Li HY, Carlomagno F. Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. Sci Rep. 2021 08 09; 11(1):16103.
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
-
Von Suskil M, Sultana KN, Elbezanti WO, Al-Odat OS, Chitren R, Tiwari AK, Challagundla KB, Srivastava SK, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma. Int J Mol Sci. 2021 May 27; 22(11).
-
Saha D, Ryan KR, Lakkaniga NR, Smith EL, Frett B. Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem. 2021 05 18; 16(10):1605-1608.
-
Jenkins SV, Alimohammadi M, Terry AS, Griffin RJ, Tackett AJ, Leung JW, Vang KB, Byrum SD, Dings RPM. Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. Angiogenesis. 2021 08; 24(3):597-611.
-
Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. Eur J Med Chem. 2021 Apr 15; 216:113265.
-
Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discov. 2021 03; 11(3):714-735.
-
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
-
Adderley JD, John von Freyend S, Jackson SA, Bird MJ, Burns AL, Anar B, Metcalf T, Semblat JP, Billker O, Wilson DW, Doerig C. Analysis of erythrocyte signalling pathways during Plasmodium falciparum infection identifies targets for host-directed antimalarial intervention. Nat Commun. 2020 08 11; 11(1):4015.
-
Lakkaniga NR, Zhang L, Belachew B, Gunaganti N, Frett B, Li HY. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. Eur J Med Chem. 2020 Oct 01; 203:112589.
-
Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, Chenbhanich J, Heike CL, Adam MP, Chang I, Sun A, Miller DE, Beck AE, Gupta D, Boos MD, Zackai EH, Everman D, Ganapathi S, Wilson M, Christodoulou J, Zarate YA, Curry C, Li D, Guimier A, Amiel J, Hakonarson H, Webster R, Bhoj EJ, Perkins JA, Dahl JP, Dobyns WB. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020 07; 182(7):1576-1591.
-
Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. J Med Chem. 2020 05 14; 63(9):4506-4516.
-
Arshad J, Ahmed J, Subhawong T, Trent JC. Progress in determining response to treatment in gastrointestinal stromal tumor. Expert Rev Anticancer Ther. 2020 04; 20(4):279-288.
-
Balasubramaniam M, Lakkaniga NR, Dera AA, Fayi MA, Abohashrh M, Ahmad I, Chandramoorthy HC, Nalini G, Rajagopalan P. FCX-146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second-generation arylidene indanone scaffold. Biotechnol Appl Biochem. 2021 Feb; 68(1):82-91.
-
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol Oncol. 2020 02; 156(2):301-307.
-
Da Vi? MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kort?m KM. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. Oncologist. 2020 02; 25(2):112-118.
-
Saha D, Kharbanda A, Yan W, Lakkaniga NR, Frett B, Li HY. The Exploration of Chirality for Improved Druggability within the Human Kinome. J Med Chem. 2020 01 23; 63(2):441-469.
-
David MP, Funderburg A, Selig JP, Brown R, Caliskan PM, Cove L, Dicker G, Hoffman L, Horne T, Gardner JM. Perspectives of Patients With Dermatofibrosarcoma Protuberans on Diagnostic Delays, Surgical Outcomes, and Nonprotuberance. JAMA Netw Open. 2019 08 02; 2(8):e1910413.
-
Robb R, Yang L, Shen C, Wolfe AR, Webb A, Zhang X, Vedaie M, Saji M, Jhiang S, Ringel MD, Williams TM. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clin Cancer Res. 2019 08 01; 25(15):4749-4760.
-
Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J. Indeed, Nuance Matters. J Thorac Oncol. 2019 01; 14(1):e16-e17.
-
Yan W, Lakkaniga NR, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li HY. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. J Med Chem. 2019 02 28; 62(4):1731-1760.
-
Zhang J, Xiang Z, Malaviarachchi PA, Yan Y, Baltz NJ, Emanuel PD, Liu YL. PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia. Cell Signal. 2018 Oct; 50:72-79.
-
Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J. "Teachable Moment" Interventions in Lung Cancer: Why Action Matters. J Thorac Oncol. 2018 05; 13(5):603-605.
-
Pakravan M, Beni AN, Ghahari E, Varshochian R, Yazdani S, Esfandiari H, Ahmadieh H. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma. Am J Ther. 2017 Nov/Dec; 24(6):e676-e680.
-
Bendell JC, Joseph M, Barnes K, Mainwaring M, Shipley D, Reddy C, Blakely L, Blachly R, Lane CM, Earwood C, Kuzur M. A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. Cancer Invest. 2017 Jul 03; 35(6):386-392.
-
Kreys ED, Frei CR, Villarreal SM, Bollinger MJ, Jones X, Koeller JM. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. Pharmacotherapy. 2017 03; 37(3):278-286.
-
Socola F, Hawes V, Lobo RH, Sasapu A. Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature. J Glob Oncol. 2018 09; 4:1-4.
-
Xi JB, Fang YF, Frett B, Zhu ML, Zhu T, Kong YN, Guan FJ, Zhao Y, Zhang XW, Li HY, Ma ML, Hu W. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in?vitro and in?vivo antitumor activities. Eur J Med Chem. 2017 Jan 27; 126:1083-1106.
-
Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016 10 01; 90(19):8924-33.
-
Koziol-White CJ, Yoo EJ, Cao G, Zhang J, Papanikolaou E, Pushkarsky I, Andrews A, Himes BE, Damoiseaux RD, Liggett SB, Di Carlo D, Kurten RC, Panettieri RA. Inhibition of PI3K promotes dilation of human small airways in a rho kinase-dependent manner. Br J Pharmacol. 2016 09; 173(18):2726-38.
-
Smith JA, Mayeux PR, Schnellmann RG. Delayed Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibition by Trametinib Attenuates Systemic Inflammatory Responses and Multiple Organ Injury in Murine Sepsis. Crit Care Med. 2016 08; 44(8):e711-20.
-
Shiver MB, Mahmoud F, Gao L. More on Merkel-Cell Carcinoma. N Engl J Med. 2016 02 04; 374(5):495.
-
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.
-
Sanjari N, Pakravan M, Nourinia R, Esfandiari H, Hafezi-Moghadam A, Zandi S, Nakao S, Shah-Heidari MH, Jamali A, Yaseri M, Ahmadieh H. Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) for Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy. J Clin Pharmacol. 2016 06; 56(6):749-53.
-
Firwana B, Sonbol MB, Diab M, Raza S, Hasan R, Yousef I, Zarzour A, Garipalli A, Doll D, Murad MH, Al-Kali A. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Int J Cancer. 2016 Mar 15; 138(6):1545-53.
-
Shiver MB, Mahmoud F, Gao L. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma. N Engl J Med. 2015 Oct 15; 373(16):1580-2.
-
Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
-
Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G. Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia. 2016 Apr; 30(4):976-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|